Diabetes Health Center
Type 2 Diabetes in Children - References
Citations
Curtis J, et al. (2001). Diagnosis and short-term clinical consequences of diabetes in children and adolescents. In HC Gerstein, RB Haynes, eds., Evidence-Based Diabetes Care, pp. 107-123. Hamilton, ON: BC Decker.
American Diabetes Association (2000). Type 2 diabetes in children and adolescents (Consensus Statement, 2000). Diabetes Care, 23(3): 381-389.
Fagot-Campagna A (2000). Emergence of type 2 diabetes mellitus in children: Epidemiological evidence. Journal of Pediatric Endocrinology and Metabolism, 13(Suppl 6): S1395-S1402.
Orr DP (2008). Diabetes mellitus. In LS Neinstein, ed., Adolescent Health Care: A Practical Guide, 5th ed., pp. 170-178. Philadelphia: Lippincott Williams and Wilkins.
American Diabetes Association (2008). Standards of medical care in diabetes. Diabetes Care, 31(Suppl 1): S12-S54.
American Diabetes Association (2004). Preventive foot care in diabetes. Clinical Practice Recommendations 2004. Diabetes Care, 27(Suppl 1): S63-S64.
American Diabetes Association (2009). Standards of medical care in diabetes. Clinical Practice Recommendations 2009. Diabetes Care, 32(Suppl 1): S13-S61.
U.S. Department of Health and Human Services (2008). 2008 Physical Activity Guidelines for Americans (ODPHP Publication No. U0036). Washington, DC: U.S. Government Printing Office. Available online: http://www.health.gov/paguidelines/pdf/paguide.pdf.
Sinha R, et al. (2002). Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. New England Journal of Medicine, 346(11): 802-810.
Diabetes Prevention Program Research Group (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6): 393-403.
Savoye M, et al. (2007). Effects of a weight management program on body composition and metabolic parameters in overweight children: A randomized controlled trial. JAMA, 297(24): 2697-2704.
Bennett PH, et al. (2003). Other risk factors section of Epidemiology of diabetes mellitus. In D Porte Jr et al., eds., Ellenberg and Rifkin's Diabetes Mellitus, 6th ed., p. 290. New York: McGraw-Hill.
Goguen JM, Leiter LA (2001). Alternative therapy: The role of selected minerals, vitamins, fiber, and herbs in treating hyperglycemia. In HC Gerstein, RB Haynes, eds., Evidence-Based Diabetes Care, pp. 295-322. Hamilton, ON: BC Decker.
Other Works Consulted
Arslanian SA (2000). Type 2 diabetes mellitus in children: Pathophysiology and risk factors. Journal of Pediatric Endocrinology and Metabolism, 13(Suppl 6): 1385-1394.
Chase HP, Eisenbarth GS (2007). Diabetes mellitus. In WW Hay et al., eds., Current Pediatric Diagnosis and Treatment, 18th ed., pp. 978-985. New York: McGraw-Hill.
Committee on Nutrition, American Academy of Pediatrics (2003). Policy statement: Prevention of pediatric overweight and obesity. Pediatrics, 112(2): 424-430.
Laffel L, et al (2005). Treatment of the child and adolescent with diabetes. In CR Kahn et al., eds., Joslin's Diabetes Mellitus, 14th ed., pp. 711-736. Philadelphia: Lippincott Williams and Wilkins.
Riddle MC, Genuth S (2007). Type 2 diabetes mellitus. In DC Dale, DD Federman, eds., ACP Medicine, section 9, chap. 2. New York: WebMD.
Silverstein JH, Rosenbloom AL (2000). Treatment of type 2 diabetes mellitus in children and adolescents. Journal of Pediatric Endocrinology and Metabolism, 13(Suppl 6): 1403-1409.
WebMD Medical Reference from Healthwise
Type 2 Diabetes in Children Topics
Important Safety Information
Do not take UROXATRAL if you have liver problems or if you are taking antifungal drugs like ketoconazole or itraconazole, or HIV drugs like ritonavir.
UROXATRAL can cause a sudden drop in blood pressure, especially when starting treatment. This may lead to fainting, dizziness, and lightheadedness. Do not drive, operate machinery, or do any dangerous activity until you know how UROXATRAL will affect you. This is especially important if you already have a problem with low blood pressure or take medicines to treat high blood pressure. There may be an increased risk of low blood pressure and fainting when taking UROXATRAL in combination with blood pressure medication or nitrates, or erectile dysfunction medication.
If considering cataract surgery (clouding of the eyes), tell your eye surgeon that you are currently taking UROXATRAL or have previously been treated with an alpha-blocker.
Before taking UROXATRAL, tell your doctor if you have kidney problems.
Also, tell your doctor if you or any family member(s) have or take medications for a rare heart condition known as congenital prolongation of the QT interval.
BPH and prostate cancer can cause the same symptoms. However, UROXATRAL is not a treatment for prostate cancer.
The most common side effects with UROXATRAL are dizziness, upper respiratory tract infection, headache, and tiredness.
Indication
Uroxatral® (alfuzosin HCl 10 mg extended-release tablets) is an alpha1-blocker for the treatment of the signs and symptoms of BPH.
Please see UROXATRAL full prescribing information.
Vinegar is in everything from coleslaw to pickles. What if you could actually use it to help prevent disease?
